Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A prespecified FIGARO-DKD subgroup analysis of 325 Chinese adults with type 2 diabetes and CKD found a significant reduction in the secondary kidney outcome with finerenone but no significant cardiovascular benefit. PICO summary and expert commentary.
A 2x2 cluster RCT in 284 adults with type 2 diabetes and overweight or obesity testing whether nudge-based dietary education and tableware lower HbA1c. PICO summary and expert commentary.
A small randomized trial of CGM-guided insulin titration in cardiac surgery patients with type 2 diabetes and prediabetes missed its primary time-in-range endpoint but improved several secondary glucose metrics. PICO summary and expert commentary.
A small single-site quasi-experimental study tested whether an Information-Motivation-Behavioral Skills education programme raises medication adherence in older adults with type 2 diabetes. PICO summary and expert commentary.
An unblinded randomized trial testing whether adding the Vitadio self-management app to standard care improves HbA1c in type 2 diabetes. PICO summary and expert commentary.
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
A small single-centre randomised trial testing weight-lowering hypoglycaemic agents plus a high-protein diet and moderate exercise against standard care for diabetes remission in adults with obesity. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
A 149-patient inpatient randomized trial found an AI insulin titration system noninferior to senior physicians for time-in-range glucose control. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
